Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Kathryn Horwitz to Receptors, Estrogen

This is a "connection" page, showing publications Kathryn Horwitz has written about Receptors, Estrogen.

 
Connection Strength
  
 
 
3.921
  
  1. Ogba N, Manning NG, Bliesner BS, Ambler SK, Haughian JM, Pinto MP, Jedlicka P, Joensuu K, Heikkil? P, Horwitz KB. Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells. Breast Cancer Res. 2014 Dec 05; 16(6):489.
    View in: PubMed
    Score: 0.378
  2. Knox AJ, Scaling AL, Pinto MP, Bliesner BS, Haughian JM, Abdel-Hafiz HA, Horwitz KB. Modeling luminal breast cancer heterogeneity: combination therapy to suppress a hormone receptor-negative, cytokeratin 5-positive subpopulation in luminal disease. Breast Cancer Res. 2014 Aug 13; 16(4):418.
    View in: PubMed
    Score: 0.370
  3. Spillman MA, Manning NG, Dye WW, Sartorius CA, Post MD, Harrell JC, Jacobsen BM, Horwitz KB. Tissue-specific pathways for estrogen regulation of ovarian cancer growth and metastasis. Cancer Res. 2010 Nov 01; 70(21):8927-36.
    View in: PubMed
    Score: 0.284
  4. Pinto MP, Badtke MM, Dudevoir ML, Harrell JC, Jacobsen BM, Horwitz KB. Vascular endothelial growth factor secreted by activated stroma enhances angiogenesis and hormone-independent growth of estrogen receptor-positive breast cancer. Cancer Res. 2010 Apr 01; 70(7):2655-64.
    View in: PubMed
    Score: 0.273
  5. Horwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CA. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci U S A. 2008 Apr 15; 105(15):5774-9.
    View in: PubMed
    Score: 0.238
  6. Harrell JC, Dye WW, Harvell DM, Pinto M, Jedlicka P, Sartorius CA, Horwitz KB. Estrogen insensitivity in a model of estrogen receptor positive breast cancer lymph node metastasis. Cancer Res. 2007 Nov 01; 67(21):10582-91.
    View in: PubMed
    Score: 0.231
  7. Harrell JC, Dye WW, Allred DC, Jedlicka P, Spoelstra NS, Sartorius CA, Horwitz KB. Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Cancer Res. 2006 Sep 15; 66(18):9308-15.
    View in: PubMed
    Score: 0.214
  8. Harvell DM, Richer JK, Allred DC, Sartorius CA, Horwitz KB. Estradiol regulates different genes in human breast tumor xenografts compared with the identical cells in culture. Endocrinology. 2006 Feb; 147(2):700-13.
    View in: PubMed
    Score: 0.201
  9. Jacobsen BM, Schittone SA, Richer JK, Horwitz KB. Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. Mol Endocrinol. 2005 Mar; 19(3):574-87.
    View in: PubMed
    Score: 0.189
  10. Graham JD, Bain DL, Richer JK, Jackson TA, Tung L, Horwitz KB. Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer. Steroids. 2000 Oct-Nov; 65(10-11):579-84.
    View in: PubMed
    Score: 0.141
  11. Horwitz KB. Bringing estrogen receptors under control. Breast Cancer Res. 1999; 1(1):5-7.
    View in: PubMed
    Score: 0.131
  12. Horwitz KB. Mechanisms of hormone resistance in breast cancer. Breast Cancer Res Treat. 1993; 26(2):119-30.
    View in: PubMed
    Score: 0.083
  13. Leslie KK, Tasset DM, Horwitz KB. Functional analysis of a mutant estrogen receptor isolated from T47Dco breast cancer cells. Am J Obstet Gynecol. 1992 Apr; 166(4):1053-61.
    View in: PubMed
    Score: 0.078
  14. Horwitz KB. Cellular heterogeneity and mutant oestrogen receptors in hormone resistant breast cancer. Cancer Surv. 1992; 14:41-54.
    View in: PubMed
    Score: 0.077
  15. Haughian JM, Pinto MP, Harrell JC, Bliesner BS, Joensuu KM, Dye WW, Sartorius CA, Tan AC, Heikkil? P, Perou CM, Horwitz KB. Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2742-7.
    View in: PubMed
    Score: 0.076
  16. Graham ML, Krett NL, Miller LA, Leslie KK, Gordon DF, Wood WM, Wei LL, Horwitz KB. T47DCO cells, genetically unstable and containing estrogen receptor mutations, are a model for the progression of breast cancers to hormone resistance. Cancer Res. 1990 Oct 01; 50(19):6208-17.
    View in: PubMed
    Score: 0.071
  17. Cappelletti V, Patriarca C, Granata G, Cattoretti G, Coradini D, Di Fronzo G, Horwitz K. Progesterone receptor determination in human breast tumors by immunocytochemical and biochemical techniques. Breast Cancer Res Treat. 1989 Nov; 14(2):217-25.
    View in: PubMed
    Score: 0.066
  18. Harvell DM, Richer JK, Singh M, Spoelstra N, Finlayson C, Borges VF, Elias AD, Horwitz KB. Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor. Breast Cancer Res Treat. 2008 Dec; 112(3):489-501.
    View in: PubMed
    Score: 0.059
  19. Sartorius CA, Harvell DM, Shen T, Horwitz KB. Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth. Cancer Res. 2005 Nov 01; 65(21):9779-88.
    View in: PubMed
    Score: 0.050
  20. Fuqua SA, Cui Y, Lee AV, Osborne CK, Horwitz KB. Insights into the role of progesterone receptors in breast cancer. J Clin Oncol. 2005 Feb 01; 23(4):931-2; author reply 932-3.
    View in: PubMed
    Score: 0.048
  21. Horwitz KB. Is a functional estrogen receptor always required for progesterone receptor induction in breast cancer? J Steroid Biochem. 1981 Dec; 15:209-17.
    View in: PubMed
    Score: 0.038
  22. Horwitz KB, Aiginger P, Kuttenn F, McGuire WL. Nuclear estrogen receptor release from antiestrogen suppression: amplified induction of progesterone receptor in MCF-7 human breast cancer cells. Endocrinology. 1981 May; 108(5):1703-9.
    View in: PubMed
    Score: 0.037
  23. Graham JD, Bain DL, Richer JK, Jackson TA, Tung L, Horwitz KB. Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring? J Steroid Biochem Mol Biol. 2000 Nov 30; 74(5):255-9.
    View in: PubMed
    Score: 0.036
  24. Horwitz KB, McGuire WL. Nuclear estrogen receptors. Effect of inhibitors on processing and steady state levels. J Biol Chem. 1980 Oct 25; 255(20):9699-705.
    View in: PubMed
    Score: 0.036
  25. Hodges YK, Tung L, Yan XD, Graham JD, Horwitz KB, Horwitz LD. Estrogen receptors alpha and beta: prevalence of estrogen receptor beta mRNA in human vascular smooth muscle and transcriptional effects. Circulation. 2000 Apr 18; 101(15):1792-8.
    View in: PubMed
    Score: 0.034
  26. Hodges YK, Richer JK, Horwitz KB, Horwitz LD. Variant estrogen and progesterone receptor messages in human vascular smooth muscle. Circulation. 1999 May 25; 99(20):2688-93.
    View in: PubMed
    Score: 0.032
  27. Horwitz KB, McGuire WL. Estrogen control of progesterone receptor induction in human breast cancer: role of nuclear estrogen receptor. Adv Exp Med Biol. 1979; 117:95-110.
    View in: PubMed
    Score: 0.031
  28. Horwitz KB, McGuire WL. Nuclear mechanisms of estrogen action. Effects of estradiol and anti-estrogens on estrogen receptors and nuclear receptor processing. J Biol Chem. 1978 Nov 25; 253(22):8185-91.
    View in: PubMed
    Score: 0.031
  29. Horwitz KB, McGuire WL. Actinomycin D prevents nuclear processing of estrogen receptor. J Biol Chem. 1978 Sep 25; 253(18):6319-22.
    View in: PubMed
    Score: 0.031
  30. Horwitz KB, McGuire WL. Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. J Biol Chem. 1978 Apr 10; 253(7):2223-8.
    View in: PubMed
    Score: 0.030
  31. Hovland AR, Powell RL, Takimoto GS, Tung L, Horwitz KB. An N-terminal inhibitory function, IF, suppresses transcription by the A-isoform but not the B-isoform of human progesterone receptors. J Biol Chem. 1998 Mar 06; 273(10):5455-60.
    View in: PubMed
    Score: 0.030
  32. Horwitz KB. When tamoxifen turns bad. Endocrinology. 1995 Mar; 136(3):821-3.
    View in: PubMed
    Score: 0.024
  33. Horwitz KB. How do breast cancers become hormone resistant? J Steroid Biochem Mol Biol. 1994 Jun; 49(4-6):295-302.
    View in: PubMed
    Score: 0.023
  34. Horwitz KB. Hormone 'resistance' in breast cancer: the role of normal and mutant steroid receptors. Cancer Treat Res. 1994; 71:111-27.
    View in: PubMed
    Score: 0.022
  35. Horwitz KB. Hormone-resistant breast cancer or "feeding the hand that bites you". Prog Clin Biol Res. 1994; 387:29-45.
    View in: PubMed
    Score: 0.022
  36. Horwitz KB. Can hormone "resistant" breast cancer cells be inappropriately stimulated by tamoxifen? Ann N Y Acad Sci. 1993 Jun 11; 684:63-74.
    View in: PubMed
    Score: 0.021
  37. Badtke MM, Jambal P, Dye WW, Spillman MA, Post MD, Horwitz KB, Jacobsen BM. Unliganded progesterone receptors attenuate taxane-induced breast cancer cell death by modulating the spindle assembly checkpoint. Breast Cancer Res Treat. 2012 Jan; 131(1):75-87.
    View in: PubMed
    Score: 0.018
  38. Harvell DM, Spoelstra NS, Singh M, McManaman JL, Finlayson C, Phang T, Trapp S, Hunter L, Dye WW, Borges VF, Elias A, Horwitz KB, Richer JK. Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. Breast Cancer Res Treat. 2008 Dec; 112(3):475-88.
    View in: PubMed
    Score: 0.015
  39. Bray JD, Jelinsky S, Ghatge R, Bray JA, Tunkey C, Saraf K, Jacobsen BM, Richer JK, Brown EL, Winneker RC, Horwitz KB, Lyttle CR. Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells. J Steroid Biochem Mol Biol. 2005 Dec; 97(4):328-41.
    View in: PubMed
    Score: 0.012
  40. Horwitz KB, Wei LL, Sedlacek SM, d'Arville CN. Progestin action and progesterone receptor structure in human breast cancer: a review. Recent Prog Horm Res. 1985; 41:249-316.
    View in: PubMed
    Score: 0.012
  41. Sedlacek SM, Horwitz KB. The role of progestins and progesterone receptors in the treatment of breast cancer. Steroids. 1984 Dec; 44(6):467-84.
    View in: PubMed
    Score: 0.012
  42. Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, Horwitz KB, Fuqua SA. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res. 2004 Apr 15; 10(8):2751-60.
    View in: PubMed
    Score: 0.011
  43. Wu J, Richer J, Horwitz KB, Hyder SM. Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B. Cancer Res. 2004 Mar 15; 64(6):2238-44.
    View in: PubMed
    Score: 0.011
  44. Horwitz KB, Mockus MB, Lessey BA. Variant T47D human breast cancer cells with high progesterone-receptor levels despite estrogen and antiestrogen resistance. Cell. 1982 Mar; 28(3):633-42.
    View in: PubMed
    Score: 0.010
  45. Edwards DP, Martin PM, Horwitz KB, Chamness GC, McGuire WL. Subcellular compartmentalization of estrogen receptors in human breast cancer cells. Exp Cell Res. 1980 May; 127(1):197-213.
    View in: PubMed
    Score: 0.009
  46. Horwitz KB, McGuire WL. Studies on mechanisms of estrogen and antiestrogen action in human breast cancer. Recent Results Cancer Res. 1980; 71:45-58.
    View in: PubMed
    Score: 0.008
  47. Martin PM, Horwitz KB, Ryan DS, McGuire WL. Phytoestrogen interaction with estrogen receptors in human breast cancer cells. Endocrinology. 1978 Nov; 103(5):1860-7.
    View in: PubMed
    Score: 0.008
  48. Horwitz KB, Zava DT, Thilagar AK, Jensen EM, McGuire WL. Steroid receptor analyses of nine human breast cancer cell lines. Cancer Res. 1978 Aug; 38(8):2434-7.
    View in: PubMed
    Score: 0.008
  49. McGuire WL, Zava DT, Horwitz KB, Garola RE, Chamness GC. Receptors and breast cancer: do we know it all? J Steroid Biochem. 1978 May; 9(5):461-6.
    View in: PubMed
    Score: 0.007
  50. McGuire WL, Horwitz KB, Zava DT, Garola RE, Chamness GC. Hormones in breast cancer: update 1978. Metabolism. 1978 Apr; 27(4):487-501.
    View in: PubMed
    Score: 0.007
  51. McGuire WL, Horwitz KB, Pearson OH, Segaloff A. Current status of estrogen and progesterone receptors in breast cancer. Cancer. 1977 Jun; 39(6 Suppl):2934-47.
    View in: PubMed
    Score: 0.007
  52. Horwitz KB, McGuire WL. Progesterone and progesterone receptors in experimental breast cancer. Cancer Res. 1977 Jun; 37(6):1733-8.
    View in: PubMed
    Score: 0.007
  53. Zava DT, Chamness GC, Horwitz KB, McGuire WL. Human breast cancer: biologically active estrogen receptor in the absence of estrogen? Science. 1977 May 06; 196(4290):663-4.
    View in: PubMed
    Score: 0.007
  54. McGuire WL, Chamness GC, Horwitz KB, Zava DT. Prolactin and estrogen receptors in breast cancer. Pathobiol Annu. 1977; 7:191-211.
    View in: PubMed
    Score: 0.007
  55. McGuire WL, Horwitz KB, De La Garza M. Selecting endocrine therapy in breast cancer. Curr Top Mol Endocrinol. 1976; 4:28-35.
    View in: PubMed
    Score: 0.006
  56. McGuire WL, Zava DT, Horwitz KB, Chamness GC. Steroid receptors in breast tumors--current status. Curr Top Exp Endocrinol. 1978; 3:93-129.
    View in: PubMed
    Score: 0.002
  57. McGuire WL, Horwitz KB, Chamness GC, Zava DT. A physiological role for estrogen and progesterone in breast cancer. J Steroid Biochem. 1976 Nov-Dec; 7(11-12):875-82.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)